On the second day of BLM administration, ELISA analysis showed that the inflammatory mediators IL‐1β (Fig. 2A) and IL‐6 (Fig. 2B), the MCP‐1 (Fig. 2C), the MPO activity (Fig. 2D) were significant increased than control group (P < 0.001). The gene discussed is IL1B; the disease is Bloom syndrome.